|
WO2021048330A1
|
|
Recombinant igg fc multimers for the treatment of immune complex-mediated kidney disorders
|
|
WO2021001522A1
|
|
A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
|
|
WO2020187969A1
|
|
Factor ix variants and uses thereof in therapy
|
|
WO2020021060A1
|
|
Infusion device having a syringe plunger control comprising a joystick
|
|
WO2020021056A1
|
|
Infusion device having a gripper mechanism
|
|
KR20200100771A
|
|
Protein purification and virus inactivation by alkyl glycosides
|
|
US2021095006A1
|
|
RECOMBINANT IgG Fc MULTIMERS FOR THE TREATMENT OF NEUROMYELITIS OPTICA
|
|
KR20200019749A
|
|
21-day administration regimens and methods thereof for fusion proteins comprising Factor IX and human albumin for prophylactic treatment of hemophilia
|
|
CA3068098A1
|
|
Modulation of fviii immunogenicity by truncated vwf
|
|
SG11201903950UA
|
|
Truncated von willebrand factor polypeptides for treating hemophilia
|
|
US2020093901A1
|
|
Subcutaneous administration of long-acting factor ix in humans
|
|
AU2017204955A1
|
|
Mutated truncated von Willebrand Factor
|
|
AU2016363789A1
|
|
Improved media for the expression of recombinant vitamin K-dependent proteins
|
|
AU2016231327A1
|
|
Modified von Willebrand factor having improved half-life
|
